A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Establish Safety, Lack of Immunogenicity, Tolerability, Pharmacokinetic Parameters, Target Engagement and Pharmacodynamic Effects

Trial Profile

A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Establish Safety, Lack of Immunogenicity, Tolerability, Pharmacokinetic Parameters, Target Engagement and Pharmacodynamic Effects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs PRS 080 (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; First in man
  • Sponsors Pieris; Pieris Pharmaceuticals
  • Most Recent Events

    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Dec 2015 Results from this trial were presented at the 57th Annual Meeting of the American Society of Hematology (ASH), according to a Pieris Pharmaceuticals media release.
    • 05 Nov 2015 According to a Pieris Pharmaceuticals company media release, data from this trial will be presented at the 57th Annual Meeting of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top